missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CA19-9/Sialyl Lewisa (GI Tumor Marker) Ab-1 Mouse Monoclonal Antibody, Epredia™
Alle ansehen Epredia ProdukteBeschreibung
Mucin glycoprotein is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings.
Host Species: Mouse
Clone: 121SLE
Isotype: IgM
Species Reactivity: Human. Does not react with rat. Others not tested.
Immunogen: Mucins from ovarian cyst
Molecular Weight: >400kDa
Positive Control: Colon CA
Cellular Localization: Cytoplasmic
Recommended for:
- Immunohistochemistry (Formalin/paraffin)
Spezifikation
Spezifikation
| Antigen | CA19-9/Sialyl Lewissuperscriptasuperscript (GI Tumor Marker) Ab-1 |
| Anwendungen | Immunohistochemistry (Paraffin) |
| Klassifikation | Monoclonal |
| Klon | 121SLE |
| Konzentration | 200μg/mL |
| Konjugat | Unconjugated |
| Wirtsspezies | Mouse |
| Immunogen | Mucins from ovarian cyst |
| Menge | 500 μL |
| Regulatorischer Status | IVD |
| Mehr anzeigen |
Name des Produkts
Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.
Haben Sie Verbesserungsvorschläge?